glp tirzepatide GLP-1/GIP Rx hormone GLP Tirzepatide | GLP1 | Medical

Food and Drug Administration (FDA) approval for the drug to treat fatty liver disease later this year, researchers said

Mutations in these genes are linked to monogenic obesity, characterized by early onset weight gain and hyperphagia

January 2, 2025: More People File Ozempic Lawsuits Ahead of 2025 As of January 2, 2025, there are 1,331 pending lawsuits against GLP-1 drug manufacturers as part of federal, consolidated litigation

The FDA review process typically takes 10 months, though Priority Review could shorten that to 6 months

Inositol, by contrast, has no defined plasma half-life

With clinical trials ongoing, phase 3 results arrive in 2026, guiding future treatment guidelines and potentially FDA approval